Hanx Biopharmaceuticals (Wuhan) Co Ltd
Company Profile
Business description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
Contact
No. 1 Jiufeng 1st Road
Building A8, Phase II, Bio-Innovation Park
East Lake New Technology Development Zone
Hubei
Wuhan
CHNT: +86 2765524978
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
55
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
stocks
ASX listed media giant drives strong earnings growth
stocks
ASX real estate platform outperforms yet questions remain
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,355.07 | 35.62 | 0.14% |
| Dow JONES (US) | 53,968.26 | 68.67 | -0.13% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,640.68 | 49.94 | -0.19% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,761.65 | 4.01 | 0.05% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |